Alex Zhavoronkov

Dr. Alex Zhavoronkov


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AZAlex Zhavoronkov
Alex Zhavoronkov
YIYan A. Ivanenkov
Yan A. Ivanenkov
AAAlex Aliper
Alex Aliper
MVMark S. Veselov
Mark S. Veselov
VAVladimir A. Aladinskiy
Vladimir A. Aladinskiy
AAAlán Aspuru-Guzik
Alán Aspuru-Guzik

18 December 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
DPDaniil Polykovskiy
Daniil Polykovskiy
AZAlexander Zhebrak
Alexander Zhebrak
BSBenjamin Sanchez-Lengeling
Benjamin Sanchez-Lengeling
SGSergey Golovanov
Sergey Golovanov
OTOktai Tatanov
Oktai Tatanov
AZAlex Zhavoronkov
Alex Zhavoronkov
Generative models are becoming a tool of choice for exploring the molecular space. These models learn on a large training dataset and produce novel molecular structures with similar properties. Generated structures can be utilized for virtual screening or training semi-supervized predictive models in the downstream tasks. While there are plenty of generative models, it is unclear how to compare and rank them. In this work, we introduce a benchmarking platform called Molecular Sets (MOSES) to standardize training and comparison of molecular generative models. MOSES provides training and testing datasets, and a set of metrics to evaluate the quality and diversity of generated structures. We have implemented and compared several molecular generation models and suggest to use our results as reference points for further advancements in generative chemistry research. The platform and source code are available athttps://github.com/molecularsets/moses.

23 March 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
PMPolina Mamoshina
Polina Mamoshina
AVArmando Vieira
Armando Vieira
EPEvgeny Putin
Evgeny Putin
AZAlex Zhavoronkov
Alex Zhavoronkov

4 August 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
AKArtur Kadurin
Artur Kadurin
SNSergey Nikolenko
Sergey Nikolenko
KKKuzma Khrabrov
Kuzma Khrabrov
AAAlex Aliper
Alex Aliper
AZAlex Zhavoronkov
Alex Zhavoronkov

9 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
PMPolina Mamoshina
Polina Mamoshina
LOLucy Ojomoko
Lucy Ojomoko
YYYury Yanovich
Yury Yanovich
AOAlex Ostrovski
Alex Ostrovski
ABAlex Botezatu
Alex Botezatu
AZAlex Zhavoronkov
Alex Zhavoronkov
The increased availability of data and recent advancements in artificial intelligence present the unprecedented opportunities in healthcare and major challenges for the patients, developers, providers and regulators. The novel deep learning and transfer learning techniques are turning any data about the person into medical data transforming simple facial pictures and videos into powerful sources of data for predictive analytics. Presently, the patients do not have control over the access privileges to their medical records and remain unaware of the true value of the data they have. In this paper, we provide an overview of the next-generation artificial intelligence and blockchain technologies and present innovative solutions that may be used to accelerate the biomedical research and enable patients with new tools to control and profit from their personal data as well with the incentives to undergo constant health monitoring. We introduce new concepts to appraise and evaluate personal records, including the combination-, time- and relationship-value of the data. We also present a roadmap for a blockchain-enabled decentralized personal health data ecosystem to enable novel approaches for drug discovery, biomarker development, and preventative healthcare. A secure and transparent distributed personal data marketplace utilizing blockchain and deep learning technologies may be able to resolve the challenges faced by the regulators and return the control over personal data including medical records back to the individuals.

15 May 2018 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
EPEvgeny Putin
Evgeny Putin
AAArip Asadulaev
Arip Asadulaev
YIYan Ivanenkov
Yan Ivanenkov
VAVladimir Aladinskiy
Vladimir Aladinskiy
BSBenjamin Sanchez-Lengeling
Benjamin Sanchez-Lengeling
AZAlex Zhavoronkov
Alex Zhavoronkov
In silico modeling is a crucial milestone in modern drug design & development. Although computer-aided approaches in this field are well-studied, the application of deep learning methods in this research area is at the beginning. In this work, we present an original deep neural network (DNN) architecture named RANC (Reinforced Adversarial Neural Computer) for the de novo design of novel small-molecule organic structures based on generative adversarial network (GAN) paradigm and reinforcement learning (RL). As a generator RANC uses a Differentiable neural computer (DNC), a category of neural networks, with increased generation capabilities due to the addition of an explicit memory bank, which can mitigate common problems found in adversarial settings. The comparative results have shown that RANC trained on the SMILES string representation of the molecules outperforms its first DNN-based counterpart ORGANIC by several metrics relevant to drug discovery: the number of unique structures, passing medicinal chemistry filters (MCF), Muegge criteria and high QED scores. RANC is able to generate structures that match the distributions of the key chemical features/descriptors (e.g. MW, logP, TPSA) and lengths of the SMILES strings in the training dataset. Therefore, RANC can be reasonably regarded as a promising starting point to develop novel molecules with activity against different biological targets or pathways. In addition, this approach allows scientists to save time and covers a broad chemical space populated with novel and diverse compounds.